Brighten Optix Corporation (TPEX: 6747)

Market Cap	3.37B
Revenue (ttm)	746.10M
Net Income (ttm)	149.61M
Shares Out	27.20M
EPS (ttm)	5.49
PE Ratio	22.58
Forward PE	n/a
Dividend	4.78 (3.82%)
Ex-Dividend Date	Jul 18, 2024

Volume	8,625
Average Volume	6,849
Open	125.00
Previous Close	125.00
Day's Range	124.00 - 125.00
52-Week Range	124.00 - 172.52
Beta	0.38
RSI	21.78
Earnings Date	Mar 14, 2025

About Brighten Optix

Brighten Optix Corporation researches, develops, manufactures, and sells contact lenses in Taiwan and internationally. The company offers orthokeratology, a non-invasive and reversible method of vision correction by using a hard contact lens to alter the shape of the front surface of the cornea; gas permeable lenses for single vison, multifocal, and irregular cornea and keratoconus correction, under the HiClear, So2clear, Menicon, Duette, ROSE K, Ampleye, MAXIM 3D, AND ULTRAHEALTH brand name; and soft contact lenses under the iDealsoft, Briomoi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1965
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6747

Financial Performance

In 2023, Brighten Optix's revenue was 747.30 million, an increase of 0.41% compared to the previous year's 744.27 million. Earnings were 199.24 million, a decrease of -22.02%.